
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S Alzheimer’s Therapeutic Market**

According to Intelli, the U.S Alzheimer’s Therapeutic Market size was valued at USD 5,250.5 Million in 2024 and is projected to reach USD 20,854.15 Million by 2032, growing at a CAGR of 19.32% from 2025 to 2032.



Alzheimer’s disease is a major global health concern. As life expectancy increases, the disease is becoming more widespread, placing immense strain on healthcare systems, caregivers, and economies across the globe. In the United States alone, over 6 million people live with Alzheimer’s, and someone develops the disease every 65 seconds. The prevalence is higher among older adults, with nearly one in three seniors dying with Alzheimer’s or another form of dementia. Basically, it is a progressive neurological disorder that slowly erodes memory, thinking skills with the ability to carry out simple tasks. Early symptoms often include forgetting recent events, confusion and gradually progressing to severe cognitive decline that affects language, problem-solving skills, and lose the ability to recognize loved ones. Several risk factors play a pivotal role in developing the disease including advancing age, family history, and genetics particularly the presence of the APOE-ε4 gene. Other contributing factors may include head injuries, cardiovascular disease, poor sleep, and lifestyle choices such as lack of exercise or social engagement.

**U.S Alzheimer’s Therapeutic Market Definition**

The U.S. Alzheimer’s Therapeutic Market refers to the segment of the biotechnology and pharmaceutical industry dedicated to the development, production, and commercialization of treatments aimed at managing, and potentially curing Alzheimer’s disease. Driven by an aging population, increasing prevalence, and rising healthcare investments, the U.S. Alzheimer’s therapeutic market has become a critical and expanding focus for pharmaceutical companies, biotech firms, and research institutions aiming to combat this challenging neurodegenerative disorder. Wide range of therapeutic approaches are available, used to slow down the progression of this disease, which make the U.S. Alzheimer’s therapeutic market as one of the most active and promising areas in the pharmaceutical industry.

A close-up of hands holding a tablet and a pen

Description automatically generated**U.S Alzheimer’s Therapeutic Market Overview**

Technologies advancements have significantly transformed the diagnosis of Alzheimer’s disease, enabling earlier and more accurate detection. Early detection plays a significant role in effective treatment and outcomes. Innovation in neuroimaging techniques, such as PET, MRI allow clinicians to detect structural and functional changes in the brain including amyloid plaque formation, brain atrophy, which are hallmark signs of Alzheimer’s disease. AI and machine learning are increasingly being incorporated into diagnostic tools, improving the ability to recognize pattern in brain imaging that enables more accurate predictions of disease progression. This market encompasses several therapeutic approaches, such as cholinesterase inhibitors (donepezil, galantamine, and rivastigmine), NMDA receptor antagonists (memantine), monoclonal antibodies (aducanumab and lecanemab) targeting amyloid-beta and tau proteins, and emerging disease-modifying therapies. It also includes supportive medications and interventions to manage behavioral symptoms associated with the disease. Additionally, biomarker testing through CSF and emerging blood-based assays are improving diagnostic precision by detecting abnormal levels of amyloid-beta and tau proteins.

**U.S Alzheimer’s Therapeutic Market Segmentation Analysis**

The U.S Alzheimer’s Therapeutic Market is segmented based on therapeutic approach, Drug class, Stage of disease, and Distribution channel.

**U.S Alzheimer’s Therapeutic** **Market, By Therapeutic approach**

* **Symptomatic Treatments**
* **Disease-modifying therapies (DMTs)**

The U.S. Alzheimer’s therapeutic market, when analyzed by therapeutic approach, is broadly divided into symptomatic treatments and disease-modifying therapies (DMTs). Symptomatic treatments have long been the standard of care, helping to temporarily manage cognitive and behavioral symptoms without altering disease progression. However, the market is increasingly shifting toward disease-modifying therapies that target the underlying biological mechanisms of Alzheimer’s, such as amyloid-beta plaques and tau protein tangles. This evolving therapeutic A close-up of hands holding a tablet and a pen

Description automatically generatedlandscape reflects a growing focus on early intervention and precision medicine, aiming to improve long-term outcomes and quality of life for patients.

**U.S Alzheimer’s Therapeutic** **Market, By Drug Class**

* **Cholinesterase inhibitors**
* **NMDA Receptor Antagonists**
* **Monoclonal Antibodies**
* **Combination Drugs**
* **Pipeline Drugs**

The U.S. Alzheimer’s therapeutic market, segmented by drug class, highlights a dynamic and evolving treatment landscape. Traditional drug classes such as cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (e.g., memantine) remain widely used for managing symptoms in mild to moderate stages of the disease. In 2022, the cholinesterase inhibitors segment accounted for the largest revenue share, exceeding 51.24%, solidifying its position as the standard of care in Alzheimer’s treatment. However, the market is witnessing a transformative shift with the emergence of monoclonal antibodies targeting amyloid-beta plaques. Recent FDA approves aducanumab and lecanemab, aimed at slowing disease progression. These innovative treatments aim to alter the progression of Alzheimer’s rather than just alleviate symptoms, marking a critical breakthrough in neuroscience. The pipeline for Alzheimer’s drugs in the U.S. is robust and rapidly expanding, reflecting growing momentum in the search for more effective treatments.

**U.S Alzheimer’s Therapeutic** **Market, By Stage of Disease**

* **Early-stage (Mild Cognitive Impairment)**
* A close-up of hands holding a tablet and a pen

  Description automatically generated**Mild to Moderate Alzheimer’s**
* **Severe Alzheimer’s**

The U.S. Alzheimer’s therapeutic market, when analyzed by stage of disease, reflects a growing emphasis on early detection and intervention. In the early stage, there is an increasing focus on diagnostic tools and disease modifying therapies aimed at slowing progression before significant damage occurs. Similarly, moderate stages account for the majority of therapeutic interventions. Meanwhile, in the severe stage, treatment shifts toward managing behavioral symptoms, preserving quality of life.

**U.S Alzheimer’s Therapeutic** **Market, By Distribution Channel**

* **Hospital Pharmacy**
* **Retail Pharmacy**
* **E-commerce**
* **Drug Store**

The U.S. Alzheimer’s therapeutic market, segmented by distribution channel, primarily including hospital pharmacies, retail pharmacies, and online pharmacies, each playing a pivotal role in medication accessibility and patient care. Hospital pharmacies dominate the market for advanced and specialty treatments. It is significant for newly approved monoclonal antibodies that requires close monitoring. Hospital pharmacy is also the largest market share is driven by the presence of insurance reimbursement. Retail pharmacy remains a central channel for the distribution of commonly prescribed symptomatic drugs, offering convenience and broad accessibility for patients. Drug Stores play a crucial role in the U.S. Alzheimer’s therapeutic market by serving as easily accessible points of care for patients and caregivers. They primarily dispense commonly prescribed symptomatic treatments, also providing essential services like medication counseling, prescription refills. Their widespread presence across urban and rural A close-up of hands holding a tablet and a pen

Description automatically generatedareas ensures convenience and continuity of care, making them a vital component in the distribution channel for Alzheimer’s medications. Meanwhile, E-commerce is rapidly gaining traction due to the rising demand for home delivery, chronic disease management, and telehealth services.

**Key Players**

The “U.S Alzheimer’s Therapeutic Market” study report will provide valuable insight emphasizing the U.S. market. The major players in the market are Biogen Inc., Novartis AG, AC Immune, Johnson and Johnson, Eisai Co. Ltd, H. Lundabeck A/S, Adamas pharmaceuticals, Abbvie Inc., F. Hoffmann La Roche Ltd., Taurax Pharmaceuticals Ltd, Eli Lilly, Anavex Life Sciences, Coya Therapeutics, Verge Genomics among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In January 2025, The FDA approved extended-release memantine/donepezil capsules (14-10 mg and 28-10 mg) by Amneal Pharmaceuticals. It is used to treat moderate to severe Alzheimer’s dementia.
* In January 2025, Eisai Co., Ltd. And Biogen Inc. announced FDA approval of supplemental biologics application (sBLA) for LEQEMBI® (lecanemab-irmb).
* In february 2025, NKGen Biotech Inc., earned fast track designation from the FDA for Troculeucel. It is an its investigational therapy targeting moderate Alzheimer's disease.
* A significant breakthrough in Alzheimer’s research is Eli Lilly’s Donanemab, a promising monoclonal antibody currently under regulatory review.
* The integration of artificial intelligence in diagnostics and drug development is also accelerating the pace of innovation.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S Alzheimer’s Therapeutic Market. We cover the major impacting factors driving the industry growth in the given region.

A close-up of hands holding a tablet and a pen

Description automatically generated**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the U.S Alzheimer’s Therapeutic Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generated**TABLE OF CONTENT**

1 INTRODUCTION OF U.S ALZHEIMER’S THERAPEUTIC MARKET

1.1 Overview of the Market

1.2 Scope of Report

1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY

3.1 Data Mining

* 1. Validation

3.3 Primary Interviews

3.4 List of Data Sources

4 U.S ALZHEIMER’S THERAPEUTIC MARKET OUTLOOK

4.1 Overview

4.2 Market Dynamics

### 4.2.1 Drivers

### 4.2.2 Restraints

### 4.2.3 Opportunities

### 4.2.4 Trends

A close-up of hands holding a tablet and a pen

Description automatically generated 4.3 Porters Five Force Model

* 1. Value Chain Analysis

1. **U.S ALZHEIMER’S THERAPEUTIC** **MARKET, BY THERAPEUTIC APPROACH**

5.1 Overview

5.2 Symptomatic Treatments

5.3 Disease-modifying therapies (DMTs)

**6** **U.S ALZHEIMER’S THERAPEUTIC** **MARKET, BY DRUG CLASS**

* 1. Overview

6.2 Cholinesterase inhibitors

6.3 NMDA Receptor Antagonists

* 1. Monoclonal Antibodies
  2. Combination Drugs

6.6 Pipeline Drugs

**7 U.S ALZHEIMER’S THERAPEUTIC** **MARKET, BY STAGE OF DISEASE**

7.1 Overview

7.2Hospital Pharmacy

7.3 Retail Pharmacy

7.4 E-commerce

* 1. Drug Store

8 U.S ALZHEIMER’S THERAPEUTIC MARKET COMPETITIVE LANDSCAPE

A close-up of hands holding a tablet and a pen

Description automatically generated 8.1 Overview

8.2 Company Market Ranking

8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Biogen Inc.

9.1.1 Overview

### 9.1.2 Financial Performance

### 9.1.3 Product Outlook

### 9.1.4 Key Developments

9.2 Novartis AG

### 9.2.1 Overview

### 9.2.2 Financial Performance

### 9.2.3 Product Outlook

### 9.2.4 Key Developments

9.3 AC Immune

### 9.3.1 Overview

### 9.3.2 Financial Performance

### 9.3.3 Product Outlook

### 9.3.4 Key Developments

9.4 Eisai Co.Ltd

### A close-up of hands holding a tablet and a pen Description automatically generated9.4.1 Overview

### 9.4.2 Financial Performance

### 9.4.3 Product Outlook

### 9.4.4 Key Developments

9.5 H. Lundabeck A/S

### 9.5.1 Overview

### 9.5.2 Financial Performance

### 9.5.3 Product Outlook

### 9.5.4 Key Developments

9.6 Adamas pharmaceuticals

### 9.6.1 Overview

### 9.6.2 Financial Performance

### 9.6.3 Product Outlook

### 9.6.4 Key Development

9.7 Johnson and Johnson

### 9.7.1 Overview

### 9.7.2 Financial Performance

### 9.7.3 Product Outlook

### 9.7.4 Key Developments

9.8 Abbvie Inc.

### A close-up of hands holding a tablet and a pen Description automatically generated9.8.1 Overview

### 9.8.2 Financial Performance

### 9.8.3 Product Outlook

### 9.8.4 Key Developments

9.9 F. Hoffmann La Roche Ltd.

### 9.9.1 Overview

### 9.9.2 Financial Performance

### 9.9.3 Product Outlook

### 9.9.4 Key Development

9.10 Taurax Pharmaceuticals Ltd Merck & Co

### 9.10.1 Overview

### 9.10.2 Financial Performance

### 9.10.3 Product Outlook

### Key Development

**9.11 Eli Lilly**

### 9.11.1Overview

### 9.11.2 Financial Performance

### 9.11.3 Product Outlook

### Key Development

**9.12 Anavex Life Sciences**

### A close-up of hands holding a tablet and a pen Description automatically generated9.12.1Overview

### 9.12.2 Financial Performance

### 9.12.3 Product Outlook

### 9.12.4 Key Development

**9.13 Coya Therapeutics**

### 9.13.1Overview

### 9.13.2 Financial Performance

### 9.13.3 Product Outlook

### 9.13.4 Key Development

**9.14 Verge Genomics**

### 9.14.1 Overview

### 9.14.2 Financial Performance

### 9.14.3 Product Outlook

### 9.14.4 Key Development

1. KEY DEVELOPMENTS

10.1 Product Launches/Developments

10.2 Mergers and Acquisitions

10.3 Business Expansions

10.4 Partnerships and Collaborations

11 Appendix

A close-up of hands holding a tablet and a pen

Description automatically generated 11.1 Related Research